also known as advantagene. inc., we are a massachusetts-based biotechnology company developing our proprietary immuno-oncology platforms for the treatment of solid tumors, including our gene mediated cytotoxic (gmci™) platform and our rqnestin34.5 platform. gmci™ is an "off-the-shelf" immunotherapy designed to generate a personalized, robust, and precise systemic response from the patient's own immune system against his or her cancer.
Company profile
Ticker
CADL
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Candel Therapeutics Securities Corporation ...
IRS number
522214851
CADL stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
30 May 24
DEF 14A
Definitive proxy
30 May 24
8-K
Amendments to Articles of Incorporation or Bylaws
30 May 24
424B5
Prospectus supplement for primary offering
24 May 24
8-K
Regulation FD Disclosure
23 May 24
10-Q
2024 Q1
Quarterly report
14 May 24
8-K
Candel Therapeutics Reports First Quarter 2024 Financial Results
14 May 24
8-K
Candel Therapeutics Announces Upcoming Presentations
25 Apr 24
10-K/A
2023 FY
Annual report (amended)
25 Apr 24
8-K
Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
11 Apr 24
Latest ownership filings
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 25.98 mm | 25.98 mm | 25.98 mm | 25.98 mm | 25.98 mm | 25.98 mm |
Cash burn (monthly) | 3.23 mm | 2.80 mm | 2.63 mm | 3.06 mm | 2.81 mm | 2.66 mm |
Cash used (since last report) | 8.40 mm | 7.26 mm | 6.84 mm | 7.94 mm | 7.31 mm | 6.90 mm |
Cash remaining | 17.58 mm | 18.71 mm | 19.13 mm | 18.04 mm | 18.67 mm | 19.08 mm |
Runway (months of cash) | 5.4 | 6.7 | 7.3 | 5.9 | 6.6 | 7.2 |
Institutional ownership, Q2 2023
20.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 18 |
Opened positions | 2 |
Closed positions | 6 |
Increased positions | 2 |
Reduced positions | 4 |
13F shares | Current |
---|---|
Total value | 5.60 bn |
Total shares | 6.14 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Northpond Ventures | 1.94 mm | $2.44 bn |
Northpond Ventures | 1.69 mm | $0.00 |
BEN Franklin Resources | 1.13 mm | $1.42 bn |
FMR | 452.56 k | $570.22 mm |
Vanguard | 405.76 k | $511.25 mm |
Bridgeway Capital Management | 132.60 k | $167.07 mm |
Geode Capital Management | 131.20 k | $165.32 mm |
C Citigroup | 118.61 k | $149.45 mm |
BLK Blackrock | 51.82 k | $65.30 mm |
STT State Street | 27.60 k | $34.78 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
28 Nov 23 | Paul Peter Tak | Common Stock | Payment of exercise | Dispose F | No | No | 0.9 | 43,443 | 39.10 k | 373,556 |
28 Nov 23 | Francesca Barone | Common Stock | Payment of exercise | Dispose F | No | No | 0.9 | 19,748 | 17.77 k | 186,657 |
28 Nov 23 | Seshu Tyagarajan | Common Stock | Payment of exercise | Dispose F | No | No | 0.9 | 17,328 | 15.60 k | 174,230 |
28 Nov 23 | Garrett Nichols | Common Stock | Payment of exercise | Dispose F | No | No | 0.9 | 12,175 | 10.96 k | 135,126 |
News
Why BioRestorative Therapies Stock Is Moving Higher Thursday
13 Jun 24
Candel Therapeutics To Join Russell 3000 Index, Effective At The Open Of Us Equity Markets On Monday, July 1, 2024
11 Jun 24
12 Health Care Stocks Moving In Monday's After-Market Session
3 Jun 24
Market-Moving News for May 30th
30 May 24
12 Health Care Stocks Moving In Monday's Intraday Session
27 May 24
Press releases
Candel Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
18 Jun 24
Candel Therapeutics' (NASDAQ: CADL) enLIGHTEN Discovery Platform Aims To Tackle Complexities Of Tumor Microenvironments
14 Jun 24
Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments
12 Jun 24
Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments
12 Jun 24
Candel Therapeutics' (NASDAQ: CADL) Lead Candidate CAN-2409 Combats Lung, Pancreatic And Prostate Cancers With Fast Track Designation For Three Cancers
7 Jun 24